HOME >> MEDICINE >> NEWS
First US SARS vaccine trial opens at NIH

Powerful research tools that speed up vaccine development have led to the start today of human tests for a preventive vaccine against the respiratory disease SARS. The disease killed hundreds of people around the world before it was brought under control in 2003 with aggressive conventional public health measures.

Researchers at the Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will conduct the trials. The experimental vaccine against SARS, or severe acute respiratory syndrome, will be tested on 10 healthy volunteers at the NIH Clinical Center in Bethesda, MD. The clinic will do periodic follow-up exams on each volunteer for 32 weeks.

"This experimental vaccine is an outstanding achievement by NIAID researchers," said Health and Human Services Secretary Tommy G. Thompson. "It is a model for research that could greatly shorten the time needed to create vaccines to be tested against other diseases."

"The Vaccine Research Center, a cutting-edge facility established here at NIH just five years ago, encompasses the entire spectrum of vaccine development from basic research to clinical testing," says NIH Director Elias A. Zerhouni, M.D. "This is why our team at NIAID has been able to develop this vaccine at an unprecedented pace, using technological discoveries that were not available just a few short years ago."

The primary goal of the study is to determine if the experimental vaccine is safe in people. A secondary goal is to assess how well the vaccine stimulates the immune system to produce antibodies and cellular immunity, in this case, focusing on the SARS spike protein. The spike protein protrudes from the virus' outer envelope and helps it bind to cells it infects.

SARS was spotted first in China in November 2002. The virus sickened 8,096 and killed 774 worldwide by July 2003, according to the World Health Organization (WHO). SARS was
'"/>

Contact: Linda Joy
ljoy@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
13-Dec-2004


Page: 1 2 3

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First-ever safety study of medical cannabis use in Canada launched
9. First solid evidence that the study of music promotes intellectual development
10. First medical test on CD gets good results
11. First proof that cutting Rx drugs due to cost harms health

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: First SARS vaccine trial opens NIH

(Date:5/23/2013)... Jackson, TN (PRWEB) May 23, 2013 Spring ... fit, but what’s gotten into Jackson , the city ... variety of new fitness facilities and wellness centers has transformed ... in the state. , “In any city of vibrant, ... to improve or promote health,” said Kim White, owner of ...
(Date:5/23/2013)... York (PRWEB) May 23, 2013 Parker ... the rights of victims injured by defective medical devices ... Counsel Matthew J. McCauley has been appointed Co-Lead Counsel ... Mirena IUD Products Liability Litigation (Case 7:13-md-02434-CS). The Order, ... and Liaison Counsel are to submit their proposal for ...
(Date:5/23/2013)... (HealthDay News) -- The sensation of itching is hardwired ... to a small molecule released in the spinal cord, ... Researchers say this molecule, known as natriuretic polypeptide b ... nervous system. Ultimately, this signal is experienced as an ... are similar, the researchers concluded that a similar process ...
(Date:5/23/2013)... A shortage of a critical tuberculosis drug has hampered ... to contain the spread of the highly infectious lung ... was first used in 1951 and is one of ... first-line treatment for tuberculosis (TB). Patients must take the ... U.S. Centers for Disease Control and Prevention. However, ...
(Date:5/23/2013)... is available in French . ... discovered a novel molecular mechanism that can potentially slow ... abnormal growth. In the May 23 edition of the ... of Montreal explain how they found that the anti-cancer ... from dividing. , "Cells normally monitor the availability of ...
Breaking Medicine News(10 mins):Health News:Grass Roots Wellness Initiative Builds Muscle in Jackson, Tennessee 2Health News:Grass Roots Wellness Initiative Builds Muscle in Jackson, Tennessee 3Health News:Grass Roots Wellness Initiative Builds Muscle in Jackson, Tennessee 4Health News:U.S. District Court Appoints Parker Waichman LLP’s Matthew J. McCauley to Leadership Role in Mirena IUD Litigation 2Health News:Got an Itch? Mouse Study May Help Explain Why 2Health News:Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 2Health News:Scientists discover how rapamycin slows cell growth 2
(Date:5/23/2013)... Calif. , May 23, 2013 More ... cancer may not benefit from chemotherapy and still have ... the launch of one of the largest sources of ... new website and interactive Facebook page provide recently diagnosed ... they can safely avoid chemotherapy. "We anticipate ...
(Date:5/23/2013)... May 23, 2013  Every day, their baby stopped breathing, ... his lungs. April and Bryan Gionfriddo ... true. "Quite a few doctors said he had ... April Gionfriddo , about her now 20-month-old ... would work, we would take it and run with it." ...
(Date:5/23/2013)... 23, 2013  Spring Bank Pharmaceuticals, Inc., a biopharmaceutical ... infections, today announced that it has initiated dosing in ... once daily, oral therapy for the treatment of HCV ... and is designed to assess both the safety and ... first-in-class drug for the treatment of chronic HCV infections ...
Breaking Medicine Technology:Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3
Cached News: